Results 71 to 80 of about 45,678 (244)

The prevalence of resistant arterial hypertension and secondary causes in a cohort of hypertensive patients: a single center experience [PDF]

, 2017
The prevalence of resistant hypertension (RHT) still remains unknown. Aim of the study was to investigate in a large cohort of hypertensive patients the prevalence of RHT, and to identify in these patients the secondary forms of arterial hypertension (SH)
Concistre, Antonio, Costi, Umberto, D'Ermo, Giuseppe, DE TOMA, Giorgio, DE VINCENTIS, Giuseppe, Iannucci, Gino, Letizia, Claudio, Lucia, Piernatale, Marinelli, Cristiano, Matteo, Galassi, Olmati, Federica, Pergolini, Mario Sergio, Petramala, Luigi, Tonnarini, Gian Franco   +13 more
core   +2 more sources

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF).
Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz   +11 more
doaj   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Adapting clinical guidelines to take account of multimorbidity [PDF]

, 2012
Most people with a chronic condition have multimorbidity, but clinical guidelines almost entirely focus on single conditions. It will never be possible to have good evidence for every possible combination of conditions, but guidelines could be made more ...
Alderson, P., Guthrie, B., McMurdo, M.E.T., Mercer, S.W., Payne, K.   +4 more
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction

ESC Heart Failure, 2020
Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan, Shouji Matsushima, Tomomi Ide, Hidetaka Kaku, Taiki Higo, Miyuki Tsuchihashi‐Makaya, Hiroyuki Tsutsui   +6 more
doaj   +1 more source

Alterations in vascular function in primary aldosteronism - a cardiovascular magnetic resonance imaging study [PDF]

, 2014
Introduction: Excess aldosterone is associated with increased cardiovascular risk. Aldosterone has a permissive effect on vascular fibrosis. Cardiovascular magnetic resonance imaging (CMR) allows study of vascular function by measuring aortic ...
A McCurley, A Rudolph, A Tomaschitz, B Fink, B Strauch, B Strauch, C Catena, C Delles, C Delles, CB Stehr, D Rizzoni, DA Calhoun, E M Freel, E P McQuarrie, EM Freel, G Bernini, GE Callera, GF Mitchell, GP Rossi, JM Connell, JW Funder, K Gaddam, L U Zimmerli, LU Zimmerli, MJ van Trijp, MR Robinson, NC Edwards, OJ Rider, OJ Rider, P B Mark, P Milliez, P Rerkpattanapipat, PB Mark, R Holaj, R Rocha, RB Stacey, S Boyle, S Laurent, T Indra, WJ Rogers, YH Lin   +40 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial–Mesenchymal Transition

Cellular Physiology and Biochemistry, 2017
Background: The effect of relaxin and spironolactone combined on myocardial fibrosis has not been reported. Thus, we investigated the effect of the combined therapy on isoprenaline-induced myocardial fibrosis and the mechanism.
Jiejie Cai, Xiao Chen, Xingxing Chen, Lingzhi Chen, Gaoshu Zheng, Hao Zhou, Xi Zhou   +6 more
doaj   +1 more source